COMMUNIQUÉS West-GlobeNewswire
-
Nordastro Launches Fully Personalized Astrology Book With Companion App for Daily Guidance
14/07/2026 -
Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
14/07/2026 -
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026 -
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
14/07/2026 -
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
14/07/2026 -
Dandy Unveils Polychromatic Shade™ to End the Trade-Off Between Dental Aesthetics and Affordability
14/07/2026 -
ASPN 2026 to Feature Three Abstracts on SPRINT® PNS
14/07/2026 -
Aeroflow Sleep Donates to Beds for Kids and Project Sleep to Improve Sleep Health Equity
14/07/2026 -
XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026 -
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026 -
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
14/07/2026 -
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
14/07/2026 -
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
14/07/2026 -
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14/07/2026 -
Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury
14/07/2026 -
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14/07/2026 -
Verano Hosting Grand Opening Celebration of MÜV Bradfordville on Friday, July 17th, Elevating the Company’s Retail Footprint to 86 Florida Dispensaries and 163 Locations Nationwide
14/07/2026 -
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026 -
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Pages